Opus Genetics (NASDAQ:IRD – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.01, Zacks reports. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The company had revenue of $3.87 million for the quarter, compared to analyst estimates of $1.17 million.
Opus Genetics Price Performance
Shares of NASDAQ:IRD opened at $1.06 on Friday. The stock has a market cap of $33.46 million, a P/E ratio of -0.97 and a beta of 0.22. Opus Genetics has a 12-month low of $1.06 and a 12-month high of $3.40.
Analysts Set New Price Targets
Separately, HC Wainwright started coverage on shares of Opus Genetics in a research report on Wednesday. They set a “buy” rating and a $8.00 price target for the company.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
- Five stocks we like better than Opus Genetics
- 3 Warren Buffett Stocks to Buy Now
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- Election Stocks: How Elections Affect the Stock Market
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
